Destiny Pharma looking to move on to phase III with XF-73 nasal gel | News Direct

Destiny Pharma looking to move on to phase III with XF-73 nasal gel

Destiny Pharma PLC
News release by Destiny Pharma PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | March 27, 2023 08:31 AM Eastern Daylight Time

 

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief executive Neil Clark speaks to Thomas Warner from Proactive after publishing research about the company's new nasal gel, called XF-73, in the US journal 'Infection Control & Hospital Epidemiology'.

 

Clark explains more about the benefits of the gel and how it works, and confirms that the plan is to find a partner to help fund a phase III study.

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com